Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allergan plcAGN · Entity 149298 | Director | May 02, 2018 | May 04, 2018 |
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director · Executive Chairman | May 07, 2019 | May 09, 2019 |
| Keenova Therapeutics plcNONE · Entity 28960 | Director | July 15, 2026 | July 18, 2026 |
| MYRIAD GENETICS INCMYGN · Entity 5953 | Director | June 04, 2026 | June 05, 2026 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | September 29, 2022 | October 03, 2022 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | March 31, 2017 | April 04, 2017 |
| Zoetis Inc.ZTS · Entity 679 | Director | May 13, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allergan plc
Report date May 02, 2018 · Filed May 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 263,729 |
Reported balance
After 2018-05-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-02 · Grant · Acquired 1,985 · Balance 263,729 F1: These restricted stock units shall vest 100% on the earlier of (i) the day before the 2019 Annual General Meeting of Shareholders and (ii) May 2, 2019. F2: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. |
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | IndirectPaul Bisaro LLC | 120,000 |
Reported balance
Holding disclosure · report date 2018-05-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 120,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest 100% on the earlier of (i) the day before the 2019 Annual General Meeting of Shareholders and (ii) May 2, 2019.
F2: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
Amneal Pharmaceuticals, Inc.
Report date May 07, 2019 · Filed May 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 29,454 |
Ending reported balance
After 2019-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-05-07 · Exercise / conversion · Acquired 24,983 · Balance 41,983 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 2 · 2019-05-07 · Tax withholding · Disposed 12,529 · Balance 29,454 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 74,950 |
Reported balance
After 2019-05-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-07 · Exercise / conversion · Disposed 24,983 · Balance 74,950 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: On May 7, 2018, the reporting person was granted 99,933 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4: On May 7, 2018, the reporting person was granted 99,933 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire.
Keenova Therapeutics plc
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 46,749 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 4,406 · Balance 46,749 F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
MYRIAD GENETICS INC
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,142 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 59,701 · Balance 157,142 F1: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.
TherapeuticsMD, Inc.
Report date September 29, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 5,000 |
Reported balance
After 2022-09-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-29 · Grant · Acquired 5,000 · Balance 5,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023.
ZIMMER BIOMET HOLDINGS, INC.
Report date March 31, 2017 · Filed April 04, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $121.49 | Direct | 3,095.293 |
Reported balance
After 2017-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-31 · Grant · Acquired 97.745 · Balance 3,095.293 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4: Includes 5.918 phantom stock units accrued on January 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors.
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 5.918 phantom stock units accrued on January 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Zoetis Inc.
Report date May 13, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,862 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Purchase · Acquired 2,000 · Balance 27,862 F1: The Price reported in Table I, Column 4 is the price at which these shares were purchased in a single transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: The Price reported in Table I, Column 4 is the price at which these shares were purchased in a single transaction.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Impax Laboratories, LLC
Report date May 04, 2018 · Filed May 08, 2018
Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.70 · Expires 2027-03-27 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-04 · Disposition to issuer · Disposed 850,000 · Balance 0 F1: Options disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017 (the "BCA"), according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock of Holdco equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA at a per-share exercise price equal to the per-share exercise price of such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Options disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017 (the "BCA"), according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock of Holdco equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA at a per-share exercise price equal to the per-share exercise price of such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 18, 2026 01:54 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 4,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-084774 · tm2620763-1_4seq1.xml · derivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,749 Underlying: Ordinary Shares · 4,406 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:24 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 59,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001237253-26-000004 · wk-form4_1780691093.xml · nonDerivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,142 F1 · shares: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:11 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 2,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070520 · tm2616870-3_4seq1.xml · derivative · entry 4 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,343 Underlying: Ordinary Shares · 2,685 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. F4 · derivative.exercise_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F4 · derivative.expiration_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:11 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 2,197 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-070520 · tm2616870-3_4seq1.xml · derivative · entry 3 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,028 Underlying: Ordinary Shares · 2,197 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person entered into an agreement with the Issuer pursuant to which the Reporting Person forfeited the right to receive 2,197 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the Reporting Person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F5 · price: The number of RSUs forfeited is based on a percentage. F4 · derivative.exercise_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F4 · derivative.expiration_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:11 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Tax withholdingOrdinary Shares | 619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-070520 · tm2616870-3_4seq1.xml · nonDerivative · entry 2 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,244 F2 · price: The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:11 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 2,685 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-070520 · tm2616870-3_4seq1.xml · nonDerivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. Read SEC document |
| May 14, 2026 Filed May 14, 2026 21:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | PurchaseCommon Stock | 7,500 | $3.69 | $27,637.50 |
DisclosureSEC source: 0001237253-26-000002 · wk-form4_1778793403.xml · nonDerivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,441 Read SEC document |
| May 13, 2026 Filed May 13, 2026 20:35 UTC | Zoetis Inc. ZTS · Entity 679 | PurchaseCommon Stock | 2,000 | $75.88 | $151,750.00 |
DisclosureSEC source: 0001628280-26-034642 · wk-form4_1778704514.xml · nonDerivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,862 F1 · price: The Price reported in Table I, Column 4 is the price at which these shares were purchased in a single transaction. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 01:45 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 3,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-019921 · tm267115-1_4seq1.xml · derivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,225 Underlying: Ordinary Shares · 3,984 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: Each RSU will fully vest on February 23, 2027. F2 · derivative.expiration_date: Each RSU will fully vest on February 23, 2027. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:30 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionRestricted Stock Unit · Derivative | 1,619.3325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-010671 · wk-form4_1771882216.xml · derivative · entry 2 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,619.3325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F4 · derivative.exercise_date: Each RSU vests and is settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 19, 2025. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:30 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionCommon Stock | 1,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-010671 · wk-form4_1771882216.xml · nonDerivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 01:54 UTC | Zoetis Inc. ZTS · Entity 679 | GrantRestricted Stock Unit · Derivative | 1,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-009978 · wk-form4_1771552449.xml · derivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,936 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 18, 2026; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 3,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-000777 · tm261751-1_4seq1.xml · derivative · entry 4 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,241 Underlying: Ordinary Shares · 3,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. F4 · derivative.exercise_date: On February 19, 2024, the Reporting Person was granted 13,678 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 6 below. F4 · derivative.expiration_date: On February 19, 2024, the Reporting Person was granted 13,678 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 6 below. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 2,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-000777 · tm261751-1_4seq1.xml · derivative · entry 3 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,255 Underlying: Ordinary Shares · 2,466 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person entered into an agreement with the Issuer pursuant to which the Reporting Person forfeited the right to receive 2,466 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the Reporting Person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F5 · price: The number of RSUs forfeited is based on a percentage. F4 · derivative.exercise_date: On February 19, 2024, the Reporting Person was granted 13,678 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 6 below. F4 · derivative.expiration_date: On February 19, 2024, the Reporting Person was granted 13,678 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 6 below. F6 · balance_after: Reflects that the Reporting Person received 8,183 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Tax withholdingOrdinary Shares | 854 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-000777 · tm261751-1_4seq1.xml · nonDerivative · entry 2 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,178 F2 · price: The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 3,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-000777 · tm261751-1_4seq1.xml · nonDerivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. Read SEC document |
| August 14, 2025 Filed Aug 19, 2025 01:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 4,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-079941 · tm2523680-1_4seq1.xml · derivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,538 Underlying: Ordinary Shares · 4,062 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| July 31, 2025 Filed Aug 5, 2025 00:48 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 27,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-073785 · tm2522414-11_4seq1.xml · derivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,476 Underlying: Ordinary Shares · 27,357 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. F2 · derivative.exercise_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026. F2 · derivative.expiration_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 49,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-029979 · wk-form4_1749240326.xml · nonDerivative · entry 1 Bisaro Paul · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,941 F1 · shares: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 21:21 UTC | Zoetis Inc. ZTS · Entity 679 | GrantRestricted Stock Unit · Derivative | 1,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001555280-25-000123 · wk-form4_1740086492.xml · derivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,596 Underlying: Common Stock · 1,596 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 19, 2025; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| February 08, 2025 Filed Feb 11, 2025 22:14 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionRestricted Stock Unit · Derivative | 1,225.4023 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-25-000090 · wk-form4_1739312064.xml · derivative · entry 2 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,225.4023 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F4 · derivative.exercise_date: Each RSU vests and is settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, February 8, 2022. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| February 08, 2025 Filed Feb 11, 2025 22:14 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionCommon Stock | 1,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-25-000090 · wk-form4_1739312064.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 14:24 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionRestricted Stock Unit · Derivative | 1,236.2125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-25-000042 · wk-form4_1739197461.xml · derivative · entry 2 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,236.2125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F4 · derivative.exercise_date: Each RSU vests and is settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 6, 2024. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 14:24 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionCommon Stock | 1,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-25-000042 · wk-form4_1739197461.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 21:59 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 2,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000364 · tm2432211-1_4seq1.xml · derivative · entry 4 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,119 Underlying: Ordinary Shares · 2,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. F4 · derivative.exercise_date: On February 19, 2024, the reporting person was granted 13,678 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. F4 · derivative.expiration_date: On February 19, 2024, the reporting person was granted 13,678 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 21:59 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 2,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000364 · tm2432211-1_4seq1.xml · derivative · entry 3 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,626 Underlying: Ordinary Shares · 2,052 shares Expires not disclosed F3 · derivative.exercise_price: The reporting person entered into an agreement with the issuer pursuant to which the reporting person forfeited the right to receive 2,052 RSUs that would otherwise have vested in exchange for a payment from the issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F5 · price: The number of RSUs forfeited is based on a percentage. F4 · derivative.exercise_date: On February 19, 2024, the reporting person was granted 13,678 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. F4 · derivative.expiration_date: On February 19, 2024, the reporting person was granted 13,678 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 21:59 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Tax withholdingOrdinary Shares | 489 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000364 · tm2432211-1_4seq1.xml · nonDerivative · entry 2 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,018 F2 · price: The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the issuer's ordinary shares are not listed or quoted on a recognized trading market. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 21:59 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 2,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000364 · tm2432211-1_4seq1.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:53 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027328 · wk-form4_1717793613.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,145 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 21:09 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 13,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-025515 · tm245307-5_4seq1.xml · derivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,678 Underlying: Ordinary Shares · 13,678 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit (the "RSU") will be settled in ordinary shares of the issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. F2 · derivative.expiration_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:13 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionRestricted Stock Unit · Derivative | 1,463.3937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-24-000179 · wk-form4_1707862406.xml · derivative · entry 2 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,212.3053 Underlying: Common Stock · 1,463.3937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F4 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. The RSUs vest as follows: 1,463.3937 RSUs vested on February 10, 2024; and 1,212.3053 RSUs will vest on February 8, 2025. F5 · derivative.expiration_date: Not applicable. F6 · balance_after: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, February 8, 2022; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:13 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionCommon Stock | 1,463 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-24-000179 · wk-form4_1707862406.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:57 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionRestricted Stock Unit · Derivative | 1,493.2652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-24-000137 · wk-form4_1707778638.xml · derivative · entry 2 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,493.2652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F4 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 8, 2023; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:57 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionCommon Stock | 1,493 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-24-000137 · wk-form4_1707778638.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:35 UTC | Zoetis Inc. ZTS · Entity 679 | GrantRestricted Stock Unit · Derivative | 1,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001555280-24-000083 · wk-form4_1707428117.xml · derivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,223 Underlying: Common Stock · 1,223 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 6, 2024; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:11 UTC | Keenova Therapeutics plc MNKTQ · Entity 28960 | Disposition to issuerOrdinary Shares | 32,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-119105 · tm2330745-2_4seq1.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland. F2 · kind: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy. F3 · kind: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014. Read SEC document |
| June 16, 2023 Filed Jun 29, 2023 22:51 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Disposition to issuerOrdinary Shares | 39,083 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-076467 · tm2320181-1_4seq1.xml · nonDerivative · entry 2 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,048 F1 · shares: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $279,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $325,500. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. F1 · price: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $279,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $325,500. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. F1 · balance_after: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $279,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $325,500. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. Read SEC document |
| June 16, 2023 Filed Jun 29, 2023 22:51 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 3,689 | $1.28 | $4,721.92 |
DisclosureSEC source: 0001104659-23-076467 · tm2320181-1_4seq1.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,131 Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:21 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 7,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-020715 · wk-form4_1685744491.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,450 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 5,000 | $8.47 | $42,329.50 |
DisclosureSEC source: 0001104659-23-033301 · tm239775-1_4seq1.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,820 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.3622 to $8.5000, inclusive. The reporting person undertakes to provide to Mallinckrodt plc, any security holder of Mallinckrodt plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:46 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionRestricted Stock Unit · Derivative | 1,626.8438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-23-000091 · wf-form4_167641114982160.xml · derivative · entry 2 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,651.9299 Underlying: Common Stock · 1,626.8438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 1,450.3939 RSUs will vest on February 10, 2024; and 1,201.5360 RSUs will vest on February 8, 2025. F1 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F2 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 1,450.3939 RSUs will vest on February 10, 2024; and 1,201.5360 RSUs will vest on February 8, 2025. F3 · derivative.expiration_date: Not applicable. F2 · balance_after: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 1,450.3939 RSUs will vest on February 10, 2024; and 1,201.5360 RSUs will vest on February 8, 2025. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:46 UTC | Zoetis Inc. ZTS · Entity 679 | Exercise / conversionCommon Stock | 1,626 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001555280-23-000091 · wf-form4_167641114982160.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:24 UTC | Zoetis Inc. ZTS · Entity 679 | GrantRestricted Stock Unit · Derivative | 1,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001555280-23-000049 · wf-form4_167607147269070.xml · derivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,480 Underlying: Common Stock · 1,480 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). RSUs vest and are settled in shares of Zoetis common stock on the first anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:03 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 39,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001546 · tm231710-7_4seq1.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,820 F1 · shares: The reported ordinary shares represent restricted stock units ("RSUs"), which will be settled in an equal number of MNK ordinary shares and will vest ratably on each of the first two anniversaries of MNK's emergence from Chapter 11 proceedings on June 16, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 39,083 newly awarded RSUs and 30,737 RSUs previously reported in Table II. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 16,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-027577 · wf-form4_166733465434274.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 22:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051952 · doc4.xml · derivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 10:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 1,984 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046963 · doc4.xml · derivative · entry 2 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,984 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. F2 · shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F3 · derivative.exercise_date: The RSUs vested on July 1, 2022. F3 · derivative.expiration_date: The RSUs vested on July 1, 2022. F1 · derivative.underlying_shares: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. F2 · derivative.underlying_shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 10:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 1,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046963 · doc4.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. Read SEC document |
| August 16, 2022 Filed Sep 15, 2022 01:13 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 44,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-100148 · tm2225913-1_4seq1.xml · derivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,737 Underlying: Ordinary Shares · 44,354 shares Expires not disclosed F1 · derivative.exercise_price: As previously disclosed, on August 16, 2022, Paul M. Bisaro agreed to relinquish 44,354 of the restricted stock units ("RSUs") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the "MIP"). Mallinckrodt plc ("Mallinckrodt") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. Bisaro 39,083 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence. F1 · derivative.exercise_date: As previously disclosed, on August 16, 2022, Paul M. Bisaro agreed to relinquish 44,354 of the restricted stock units ("RSUs") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the "MIP"). Mallinckrodt plc ("Mallinckrodt") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. Bisaro 39,083 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence. F1 · derivative.expiration_date: As previously disclosed, on August 16, 2022, Paul M. Bisaro agreed to relinquish 44,354 of the restricted stock units ("RSUs") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the "MIP"). Mallinckrodt plc ("Mallinckrodt") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. Bisaro 39,083 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence. Read SEC document |
| July 01, 2022 Filed Jul 7, 2022 01:10 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | GrantRestricted Stock Units · Derivative | 75,091 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-025534 · doc4.xml · derivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,091 Underlying: Ordinary Shares · 75,091 shares Expires not disclosed F1 · derivative.exercise_price: The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock. F1 · derivative.exercise_date: The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock. F1 · derivative.expiration_date: The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.